Reduced Quality of Life and Greater Psychological Distress in Vasovagal Syncope Patients Compared to Healthy Individuals

Overview

Journal Pacing Clin Electrophysiol

Date 2018 Nov 30

PMID 30488466

Citations 36

Authors

Jessica Ng

Robert S Sheldon

Debbie Ritchie

Vidya Raj

Satish R Raj

Affiliations

Soon will be listed here.

Abstract

Background: Vasovagal syncope (VVS) patients have a reduced health-related quality of life (HRQoL). There are limited data comparing HRQoL and psychological profile in VVS patients and healthy individuals. We tested the hypothesis that VVS patients have greater impairment in both HRQoL and psychological profile compared to healthy nonfainting individuals, and that both outcome measures are negatively correlated for VVS patients.

Methods: The RAND 36-Item Health Survey (RAND36), global health visual analogue scale (VAS), Hospital Anxiety and Depression Scale, Anxiety Sensitivity Index, and Positive and Negative Affect Schedule - Expanded Form were completed by healthy individuals and at baseline by VVS patients enrolled in the Second Prevention of Syncope Trial, a randomized, placebo-controlled trial of fludrocortisone for VVS.

Results: Data were available on 76 VVS patients (34 ± 14 years; 68% F) and 85 healthy participants (35 ± 11 years; 80% F). Compared to healthy participants, VVS patients reported poorer HRQoL on all scales of the RAND36 and the VAS. VVS patients had significantly greater anxiety, depression, and anxiety sensitivity (each P < 0.001). VVS patients had more negative affect (P < 0.001) and less positive affect (P = 0.003) compared to healthy participants. Anxiety, depression, and anxiety sensitivity were negatively correlated with HRQoL for VVS patients, but not for healthy participants.

Conclusion: In this first direct comparison, VVS patients have a significantly reduced HRQoL and more anxiety and depression compared to healthy nonfainting individuals. For VVS patients, there is a relationship between psychological distress and HRQoL, suggesting a potential benefit from more comprehensive assessment and treatment.

Citing Articles

Vasovagal Syncope: A Review of Current and Emerging Therapies for a Common Cardiology Condition.

Tajdini M, Behnoush A, Khalaji A, Raj S J Tehran Heart Cent. 2024; 19(1):1-5.

PMID: 39712356 PMC: 11659707. DOI: 10.18502/jthc.v19i1.15529.

Tilt training as a treatment for reflex syncope: a multimodal approach!?.

Hornikx M, Haemers P, Stans L, Robyns T, Garweg C, Ector J Front Neurosci. 2024; 18:1473687.

PMID: 39678536 PMC: 11639079. DOI: 10.3389/fnins.2024.1473687.

Neuropsychological morbidity in the First Seizure Clinic: Prominent mood symptoms and memory issues in epilepsy.

Pugh R, Vaughan D, Jackson G, Ponsford J, Tailby C Epilepsia Open. 2024; 10(1):258-268.

PMID: 39560466 PMC: 11803273. DOI: 10.1002/epi4.13103.

A higher peak heart rate during head-up tilt test predicts the therapeutic efficacy of metoprolol in vasovagal syncope.

Liu K, Liu P, Huang Z, Wu L, Xie X, Liu J BMC Cardiovasc Disord. 2024; 24(1):576.

PMID: 39425043 PMC: 11488254. DOI: 10.1186/s12872-024-04249-4.

Effectiveness analysis of deceleration capacity and traditional heart rate variability in diagnosing vasovagal syncope.

Guo Y, Lin T, Lin N, Lin H Front Cardiovasc Med. 2024; 11:1333684.

PMID: 39290211 PMC: 11405235. DOI: 10.3389/fcvm.2024.1333684.

References

Harris P, Taylor R, Thielke R, Payne J, Gonzalez N, Conde J . Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2008; 42(2):377-81. PMC: 2700030. DOI: 10.1016/j.jbi.2008.08.010. View

Hays R, Morales L . The RAND-36 measure of health-related quality of life. Ann Med. 2001; 33(5):350-7. DOI: 10.3109/07853890109002089. View

Romme J, van Dijk N, Go-Schon I, Casteelen G, Wieling W, Reitsma J . Association between psychological complaints and recurrence of vasovagal syncope. Clin Auton Res. 2011; 21(6):373-80. DOI: 10.1007/s10286-011-0125-7. View

Sheldon R, Grubb 2nd B, Olshansky B, Shen W, Calkins H, Brignole M . 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015; 12(6):e41-63. PMC: 5267948. DOI: 10.1016/j.hrthm.2015.03.029. View

Flevari P, Leftheriotis D, Repasos E, Katsaras D, Katsimardos A, Lekakis J . Fluoxetine vs. placebo for the treatment of recurrent vasovagal syncope with anxiety sensitivity. Europace. 2016; 19(1):127-131. DOI: 10.1093/europace/euw153. View

Bagai K, Song Y, Ling J, Malow B, Black B, Biaggioni I . Sleep disturbances and diminished quality of life in postural tachycardia syndrome. J Clin Sleep Med. 2011; 7(2):204-10. PMC: 3077350. View

Giada F, Silvestri I, Rossillo A, Nicotera P, Foglia Manzillo G, Raviele A . Psychiatric profile, quality of life and risk of syncopal recurrence in patients with tilt-induced vasovagal syncope. Europace. 2005; 7(5):465-71. DOI: 10.1016/j.eupc.2005.05.008. View

Gracie J, Newton J, Norton M, Baker C, Freeston M . The role of psychological factors in response to treatment in neurocardiogenic (vasovagal) syncope. Europace. 2006; 8(8):636-43. DOI: 10.1093/europace/eul073. View

Hays R, Sherbourne C, Mazel R . The RAND 36-Item Health Survey 1.0. Health Econ. 1993; 2(3):217-27. DOI: 10.1002/hec.4730020305. View

10.

Rose M, Koshman M, Spreng S, Sheldon R . The relationship between health-related quality of life and frequency of spells in patients with syncope. J Clin Epidemiol. 2001; 53(12):1209-16. DOI: 10.1016/s0895-4356(00)00257-2. View

11.

McGrady A, Bush E, Khuder S, Grubb B . Psychological and physiological factors associated with tilt table testing for neurally mediated syncopal syndromes. Pacing Clin Electrophysiol. 2001; 24(3):296-301. DOI: 10.1046/j.1460-9592.2001.00296.x. View

12.

Soteriades E, Evans J, Larson M, Chen M, Chen L, Benjamin E . Incidence and prognosis of syncope. N Engl J Med. 2002; 347(12):878-85. DOI: 10.1056/NEJMoa012407. View

13.

Di Girolamo E, Di Iorio C, Sabatini P, Leonzio L, Barbone C, Barsotti A . Effects of paroxetine hydrochloride, a selective serotonin reuptake inhibitor, on refractory vasovagal syncope: a randomized, double-blind, placebo-controlled study. J Am Coll Cardiol. 1999; 33(5):1227-30. DOI: 10.1016/s0735-1097(98)00694-9. View

14.

van Dijk N, Sprangers M, Colman N, Boer K, Wieling W, Linzer M . Clinical factors associated with quality of life in patients with transient loss of consciousness. J Cardiovasc Electrophysiol. 2006; 17(9):998-1003. DOI: 10.1111/j.1540-8167.2006.00533.x. View

15.

Reiss S, Peterson R, Gursky D, McNally R . Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behav Res Ther. 1986; 24(1):1-8. DOI: 10.1016/0005-7967(86)90143-9. View

16.

Theodorakis G, Leftheriotis D, Livanis E, Flevari P, Karabela G, Aggelopoulou N . Fluoxetine vs. propranolol in the treatment of vasovagal syncope: a prospective, randomized, placebo-controlled study. Europace. 2006; 8(3):193-8. DOI: 10.1093/europace/euj041. View

17.

Sheldon R, Raj S, Rose M, Morillo C, Krahn A, Medina E . Fludrocortisone for the Prevention of Vasovagal Syncope: A Randomized, Placebo-Controlled Trial. J Am Coll Cardiol. 2016; 68(1):1-9. DOI: 10.1016/j.jacc.2016.04.030. View

18.

Ganzeboom K, Mairuhu G, Reitsma J, Linzer M, Wieling W, van Dijk N . Lifetime cumulative incidence of syncope in the general population: a study of 549 Dutch subjects aged 35-60 years. J Cardiovasc Electrophysiol. 2006; 17(11):1172-6. DOI: 10.1111/j.1540-8167.2006.00595.x. View

19.

Zigmond A, SNAITH R . The hospital anxiety and depression scale. Acta Psychiatr Scand. 1983; 67(6):361-70. DOI: 10.1111/j.1600-0447.1983.tb09716.x. View

20.

DAntono B, Dupuis G, St-Jean K, Levesque K, Nadeau R, Guerra P . Prospective evaluation of psychological distress and psychiatric morbidity in recurrent vasovagal and unexplained syncope. J Psychosom Res. 2009; 67(3):213-22. DOI: 10.1016/j.jpsychores.2009.03.012. View